LPL Financial LLC Raises Stock Position in Integer Holdings Co. (NYSE:ITGR)

LPL Financial LLC boosted its stake in shares of Integer Holdings Co. (NYSE:ITGR - Free Report) by 26.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 44,508 shares of the medical equipment provider's stock after purchasing an additional 9,196 shares during the period. LPL Financial LLC owned about 0.13% of Integer worth $6,165,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of ITGR. Mather Group LLC. raised its position in shares of Integer by 304.3% during the 4th quarter. Mather Group LLC. now owns 190 shares of the medical equipment provider's stock valued at $25,000 after purchasing an additional 143 shares during the period. Lee Danner & Bass Inc. bought a new stake in Integer during the fourth quarter valued at about $27,000. R Squared Ltd purchased a new position in shares of Integer in the fourth quarter valued at about $44,000. Versant Capital Management Inc boosted its stake in shares of Integer by 98.4% in the fourth quarter. Versant Capital Management Inc now owns 369 shares of the medical equipment provider's stock worth $49,000 after acquiring an additional 183 shares during the period. Finally, Principal Securities Inc. grew its position in shares of Integer by 31.2% during the fourth quarter. Principal Securities Inc. now owns 639 shares of the medical equipment provider's stock worth $85,000 after purchasing an additional 152 shares in the last quarter. Institutional investors own 99.29% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ITGR. Benchmark upped their price target on Integer from $140.00 to $150.00 and gave the stock a "buy" rating in a research note on Friday, February 21st. Oppenheimer cut shares of Integer from an "outperform" rating to a "market perform" rating in a research note on Friday, February 21st. Raymond James began coverage on shares of Integer in a research note on Friday, March 28th. They issued an "outperform" rating and a $145.00 price target on the stock. Truist Financial reduced their target price on Integer from $163.00 to $140.00 and set a "buy" rating on the stock in a report on Friday. Finally, KeyCorp increased their price target on Integer from $144.00 to $154.00 and gave the company an "overweight" rating in a research note on Friday, January 24th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $146.00.

Remove Ads

Integer Trading Up 2.3 %

Shares of NYSE ITGR traded up $2.66 during midday trading on Friday, hitting $116.49. The company's stock had a trading volume of 633,871 shares, compared to its average volume of 341,053. The business's 50 day moving average is $123.88 and its two-hundred day moving average is $130.93. The firm has a market cap of $4.06 billion, a P/E ratio of 34.67, a price-to-earnings-growth ratio of 1.72 and a beta of 1.09. The company has a current ratio of 2.95, a quick ratio of 2.09 and a debt-to-equity ratio of 0.62. Integer Holdings Co. has a 12-month low of $104.93 and a 12-month high of $146.36.

Integer (NYSE:ITGR - Get Free Report) last released its quarterly earnings data on Thursday, February 20th. The medical equipment provider reported $1.43 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.03). Integer had a net margin of 6.92% and a return on equity of 11.65%. The firm had revenue of $449.50 million during the quarter, compared to the consensus estimate of $446.28 million. As a group, equities research analysts expect that Integer Holdings Co. will post 6.01 EPS for the current year.

Integer Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.